Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600067 · ClinicalTrials.gov registry record · Phase 2
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
A Phase 2 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00600067 is a Phase 2 study that has completed, run by VIVUS. The registered enrollment target is 130 participants.
The verdict
NCT00600067, a Phase 2 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
Interventions
- DRUG Placebo
- DRUG Phentermine/Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600067
The ClinicalTrials.gov registry entry for NCT00600067 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00600067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600067 about?
NCT00600067 is a clinical study titled "A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults". The purpose of the study is to determine the long-term safety and efficacy of VI-0521 (phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2 diabetic adults. Continuation of initial 6 month trial.
What is the current status of trial NCT00600067?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2008-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00600067?
The interventions under investigation include: Placebo (DRUG), Phentermine/Topiramate (DRUG).
Who is sponsoring clinical trial NCT00600067?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.